ADMA Biologics ADMA Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Business Acquisitions Pro Forma Revenue by Business | ||||||
| ADMA Bio Manufacturing | $113.74M— | —— | —— | —— | $113.72M— | |
| Plasma Collection Centers | $716K— | —— | —— | —— | $1.05M— | |
| Revenue by Business | ||||||
| ADMA Bio Manufacturing | $113.74M-7.7% | $123.29M-8.1% | $134.19M+10.0% | $121.95M+7.2% | $113.72M+1.6% | |
| Plasma Collection Centers | $716K-95.5% | $15.98M— | $0— | $0-100% | $1.05M-81.7% | |
| Nonoperating Income Expense by Business | ||||||
| ADMA Bio Manufacturing | -$187K-2,571% | -$7K+66.7% | -$21K+80.6% | -$108K-68.8% | -$64K+14.7% | |
| Plasma Collection Centers | $68K+780% | -$10K— | $0— | $0— | $0+100% | |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest by Business | ||||||
| ADMA Bio Manufacturing | 6,229,800,000%-3,090,500,000pp | 9,320,300,000%+4,174,300,000pp | 5,146,000,000%+624,900,000pp | 4,521,100,000%+600,000pp | 4,520,500,000%-507,400,000pp | |
| Plasma Collection Centers | 690,900,000%+877,200,000pp | -186,300,000%-39,900,000pp | -146,400,000%-31,200,000pp | -115,200,000%-26,800,000pp | -88,400,000%+90,000,000pp | |
| Cost Of Revenue by Business | ||||||
| ADMA Bio Manufacturing | $32.95M-2.1% | $33.64M-42.4% | $58.41M+6.7% | $54.76M+3.2% | $53.06M+10.6% | |
| Plasma Collection Centers | $793K-95.3% | $16.71M+8,602% | $192K— | $0-100% | $648K-89.6% | |
| Gain On Sale Of Investments by Business | ||||||
| ADMA Bio Manufacturing | $0— | —— | —— | —— | —— | |
| Plasma Collection Centers | $7.98M— | —— | —— | —— | —— | |
| Total Assets by Business | ||||||
| ADMA Bio Manufacturing | $429.29M-2.8% | $441.51M+9.3% | $403.92M+9.7% | $368.23M+11.6% | $330.09M+14.1% | |
| Plasma Collection Centers | $25.26M-11.4% | $28.49M+5.4% | $27.03M-7.3% | $29.16M+5.5% | $27.64M-9.3% | |
| Selling And Marketing Expense by Business | ||||||
| ADMA Bio Manufacturing | $7.2M+7.7% | $6.68M-18.0% | $8.15M+38.9% | $5.87M-2.9% | $6.04M+13.8% | |
| Plasma Collection Centers | $0— | $0— | $0— | $0— | $0— | |
| Segment Expenditure Addition To Long Lived Assets by Business | ||||||
| ADMA Bio Manufacturing | $2.52M+147% | $1.02M-93.1% | $14.65M+620% | $2.03M-56.7% | $4.7M+78.5% | |
| Plasma Collection Centers | $27K-88.9% | $244K-16.4% | $292K+4,271% | -$7K-133% | $21K-82.2% | |
| General And Administrative Expense by Business | ||||||
| ADMA Bio Manufacturing | $8.46M— | —— | $14.59M-2.4% | $14.94M+75.9% | $8.5M+10.0% | |
| Plasma Collection Centers | $0— | $0— | $0— | $0— | $0— | |
| Research And Development Expense by Business | ||||||
| ADMA Bio Manufacturing | $2.6M+88.7% | $1.38M-9.9% | $1.53M+48.2% | $1.03M+24.8% | $826K+111% | |
| Plasma Collection Centers | $0— | $0— | $0— | $0— | $0— | |
| Stock-Based Comp by Business | ||||||
| ADMA Bio Manufacturing | $0— | —— | —— | —— | $0— | |
| Plasma Collection Centers | $1.06M— | —— | —— | —— | $1.29M— | |
| Depreciation And Amortization by Business | ||||||
| ADMA Bio Manufacturing | $1.27M— | —— | —— | —— | $1.16M+1.8% | |
| Plasma Collection Centers | $565K— | —— | —— | —— | $808K+0.6% | |
| Revenue by Product | ||||||
| ASCENIV | $97.49M— | —— | —— | —— | $76.33M+27.4% | |
| BIVIGAM | $15.42M— | —— | —— | —— | $33.51M-5.8% | |
| Intermediates And Other | $833K— | —— | —— | —— | $3.87M-54.4% | |
| Revenue by Geography | ||||||
| Non Us | $1.07M-40.3% | $1.79M+627% | $246K— | $0-100% | $4.07M+42.1% | |
| US | $113.43M-17.4% | $137.38M+2.5% | $133.98M+9.8% | $121.98M+10.2% | $110.73M-3.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does ADMA Biologics break its business down?
- ADMA Biologics (ADMA) reports business acquisitions pro forma revenue by business across 2 parts — ADMA Bio Manufacturing and Plasma Collection Centers. Each is extracted from the segment footnotes and tracked over time.
- Where does ADMA Biologics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in ADMA Biologics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.